Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) Return on Equity (2016 - 2025)

Historic Return on Equity for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Q3 2025 value amounting to 0.91%.

  • Lineage Cell Therapeutics' Return on Equity fell 6000.0% to 0.91% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.91%, marking a year-over-year decrease of 6000.0%. This contributed to the annual value of 0.26% for FY2024, which is 500.0% up from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Return on Equity stood at 0.91% for Q3 2025, which was down 6000.0% from 0.5% recorded in Q2 2025.
  • Lineage Cell Therapeutics' 5-year Return on Equity high stood at 0.11% for Q3 2021, and its period low was 0.91% during Q3 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' median Return on Equity value was 0.34% (recorded in 2023), while the average stood at 0.37%.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Return on Equity skyrocketed by 3300bps in 2021 and then plummeted by -6000bps in 2025.
  • Lineage Cell Therapeutics' Return on Equity (Quarter) stood at 0.4% in 2021, then increased by 12bps to 0.35% in 2022, then grew by 5bps to 0.33% in 2023, then grew by 21bps to 0.26% in 2024, then tumbled by -250bps to 0.91% in 2025.
  • Its Return on Equity stands at 0.91% for Q3 2025, versus 0.5% for Q2 2025 and 0.23% for Q1 2025.